Hint mode is switched on Switch off
For swift navigation between sections

Eidos Therapeutics
LEI 549300VGYGU07QRG6271

Organization name
Eidos Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin amyloidosis. The company was incorporated in 2013 and is headquartered in San Francisco, California.

Awards

Documentation

IFRS/US GAAP reports

2020
2019
2018
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Codes

  • LEI
    549300VGYGU07QRG6271
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001731831
Registration is required to get access.